Personalis Reports 329% Clinical Test Surge and 239% MRD Revenue Growth
Personalis delivered a 329% year-over-year increase in clinical tests and grew biopharma MRD revenue by 239% while securing Medicare coverage for breast and lung cancer. The company ended the quarter with $240 million cash, plans to double its salesforce, reported a $23.8 million net loss and saw gross margins compress to 11%.
1. Q4 Clinical and MRD Growth
Personalis delivered a 329% year-over-year rise in clinical tests and posted 239% growth in biopharma MRD revenue, reflecting accelerating adoption of its MRD offerings across clinical and pharma research applications.
2. Medicare Coverage Milestones
The company secured Medicare coverage decisions for both breast and lung cancer MRD tests, a milestone that bolsters the credibility of its technology and supports conversations with physicians and key opinion leaders.
3. Financial Position and Margins
Ending Q4 with $240 million in cash and short-term investments, Personalis incurred a $23.8 million net loss and saw gross margins compress to 11% due to unreimbursed costs and planned declines from legacy contracts.
4. Commercial Expansion and Outlook
With plans to double its salesforce, the company aims to drive further clinical and biopharma engagement, though it remains reliant on future reimbursement developments and sector stability to sustain margin improvement.